Group 1 - Adma Biologics (ADMA) closed at $21.31, with a +0.38% change from the previous day, outperforming the S&P 500's gain of 0.13% [1] - Over the past month, ADMA shares have appreciated by 3.01%, while the Medical sector lost 8.46% and the S&P 500 lost 6.3% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.16, reflecting a 100% increase from the same quarter last year [2] - Revenue is forecasted to be $119.1 million, indicating a growth of 45.46% compared to the corresponding quarter of the prior year [2] Group 3 - Full-year Zacks Consensus Estimates predict earnings of $0.71 per share and revenue of $495.8 million, representing year-over-year changes of +44.9% and +16.26%, respectively [3] - Recent adjustments to analyst estimates for Adma Biologics indicate positive sentiment regarding the company's business and profitability [3] Group 4 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks rated 1 deliver an average annual return of +25% since 1988 [5] - Over the past month, the Zacks Consensus EPS estimate for Adma Biologics has increased by 2.16%, and the company currently holds a Zacks Rank of 2 (Buy) [5] Group 5 - Adma Biologics has a Forward P/E ratio of 29.9, which is a premium compared to the industry average Forward P/E of 15.68 [6] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [6]

Adma Biologics (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA crossed above the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.T ...

Adma Biologics (ADMA) shares rallied 7.8% in the last trading session to close at $20.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.3% gain over the past four weeks.Strong fundamentals, buoyed by broader market optimism, drove this rally for ADMA Biologics.This infectious disease drug developer is expected to post quarterly earnings of $0.16 per share in its upcoming report, which represents a year-ov ...

Core Viewpoint - ADMA Biologics (ADMA) shows significant upside potential with a mean price target of $27.33, indicating a 51.8% increase from the current trading price of $18.01 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.04, where the lowest estimate of $25 suggests a 38.8% increase, and the highest estimate of $32 indicates a potential surge of 77.7% [2] - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [8] Earnings Estimates and Analyst Sentiment - Analysts exhibit growing optimism about ADMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [10] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.2%, with one estimate moving higher and no negative revisions [11] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, further supporting the stock's potential upside [12]

Core Viewpoint - ADMA Biologics, Inc. emphasizes its strategic advantage due to fully U.S.-based manufacturing and supply chain operations, which are insulated from recent tariffs on foreign goods [1][2]. Group 1: Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB®, targeting immune deficiencies and hepatitis B [3]. - ADMA operates an FDA-licensed facility in Boca Raton, Florida, for the production of its immune globulin products and also runs FDA-approved source plasma collection through its subsidiary, ADMA BioCenters [3]. Group 2: Strategic Positioning - The company asserts that the tariffs on foreign goods will not affect its supply chain or production operations due to its fully integrated U.S.-based supply chain [2]. - ADMA's operational model ensures enhanced supply chain robustness, resilience, and regulatory compliance, aligning with federal and private sector preferences for U.S.-made products [2]. - By maintaining complete operational control within the U.S., ADMA is positioned to leverage national economic incentives and provide reliable, high-quality offerings to its domestic customers [2].

Technical Analysis - ADMA Biologics Inc has reached a key level of support, with its 50-day simple moving average crossing above the 200-day simple moving average, indicating a "golden cross" [1] - A golden cross is a bullish technical chart pattern that suggests a potential breakout, formed when a stock's short-term moving average surpasses its long-term moving average [1][2] Market Performance - ADMA has experienced a rally of 31% over the past four weeks, indicating strong upward momentum [3] - The company currently holds a 2 (Buy) rating on the Zacks Rank, suggesting positive market sentiment [3] Earnings Outlook - The earnings outlook for ADMA is positive, with no earnings estimates decreasing in the past two months and two revisions higher, leading to an increase in the Zacks Consensus Estimate [3] - This positive earnings outlook further solidifies the bullish case for ADMA [3] Investment Consideration - Investors are encouraged to consider adding ADMA to their watchlist due to the significant technical indicator and the positive movement in earnings estimates [4]

Core Viewpoint - Adma Biologics has shown strong stock performance recently, significantly outperforming the broader market and its industry, raising questions about its future trajectory [2][16]. Earnings Estimate Revisions - For the current quarter, Adma Biologics is expected to report earnings of $0.16 per share, reflecting a 100% increase year-over-year, with a 6.7% upward revision in estimates over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $0.71, indicating a 44.9% year-over-year increase, with a 3.7% upward revision in the last month [5]. - For the next fiscal year, the consensus estimate is $0.93, representing a 31% increase from the previous year, with a 6.9% upward revision [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), indicating a positive outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, showing a year-over-year increase of 45.5% [9]. - For the current fiscal year, the sales estimate is $495.8 million, indicating a 16.3% increase, while the next fiscal year's estimate is $611.5 million, reflecting a 23.3% increase [9]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics achieved revenues of $117.55 million, a 59.1% year-over-year increase, and an EPS of $0.14 compared to $0.04 a year ago [11]. - The company exceeded consensus revenue estimates in all four of the last quarters and surpassed EPS estimates three times [11]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15].

Group 1 - The article emphasizes that it is not an exhaustive analysis of the featured company and should not be interpreted as personalized investment advice [2] - It highlights that the predictions and opinions presented are based on the author's analysis and reflect a probabilistic approach, not absolute certainty [2] - The article advises readers to independently verify the information and conduct their own research before making investment decisions [2] Group 2 - The content clarifies that past performance is not a guarantee of future results and no specific investment recommendations are provided [3] - It notes that the views expressed may not reflect those of Seeking Alpha as a whole, indicating a diversity of opinions among analysts [3] - The article mentions that analysts may not be licensed or certified by any institute or regulatory body, which could impact the credibility of the analysis [3]

Core Viewpoint - Adma Biologics (ADMA) shares have increased by 22.2% in the past four weeks, closing at $19.65, with a potential upside of 39.1% based on Wall Street analysts' mean price target of $27.33 [1] Price Targets - The average price target consists of three estimates ranging from a low of $25 to a high of $32, with a standard deviation of $4.04, indicating a potential increase of 27.2% to 62.9% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price movement of ADMA shares, which can serve as a starting point for further research [7] Analyst Sentiment - Analysts have shown increasing optimism about ADMA's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, two earnings estimates for ADMA have been revised upward, leading to a 3.7% increase in the Zacks Consensus Estimate [10] Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock gains, they can provide a useful guide for understanding potential price movements [12]

Company Overview - Adma Biologics (ADMA) shares increased by 10.2% to close at $20.61, with a notable trading volume compared to normal sessions, and a total gain of 15.7% over the past four weeks [1][2] Revenue Growth - In 2024, Adma Biologics reported total revenues of $426.5 million from product sales, marking a 65% year-over-year increase [2] Earnings Expectations - The company is projected to report quarterly earnings of $0.16 per share, reflecting a 100% year-over-year change, with expected revenues of $119.1 million, up 45.5% from the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for the upcoming quarter has been revised 6.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - Adma Biologics operates within the Zacks Medical - Biomedical and Genetics industry, where Wave Life Sciences (WVE) has seen a 2.6% increase in its stock price, but has returned -11.2% over the past month [4]